Technology

The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.

EVERSANA's chief innovation discusses his experience with Apple's new device and how he thinks it might impact the life sciences industry.

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.

Portals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.

Dr. Russo discusses how modern innovations will shape the way hospitals operate in years to come.

Sasser discusses how AI is directly helping with problems specific to precision and personalized medicine research.

Webinar Date/Time: Wednesday, March 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Embracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent way of life.

Offerings include treatment plans for a considerable number of illnesses and conditions, company says.

Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?

As the technology becomes more ingrained within the Pharma industry’s processes, experts believe that regulation covering the use of AI is coming.

Study highlights how AI can identify trends and connections that can predict how new patients might respond to therapies.

The device can produce AI-assisted readings.

Each program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.

Why empowering both parties with the tools and data they need to make clinical decisions should be a top priority in the AI renaissance—to bolster patient care and improve health outcomes.

Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.

A commentary by former FDA Commissioner Scott Gottlieb, MD, addresses uncertainty regarding how the FDA will regulate new technologies, such as artificial intelligence.

Industry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

Webinar Date/Time: Tue, Jan 30, 2024 10:00 AM EST | 9:00 AM CT | 3:00 PM GMT | 4:00 PM CET

JAMA study evaluates the ability of artificial intelligence to transform electronic health.

Data will continue to grow in importance in 2024.

Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can create the greatest benefits.

Orne discusses the forces impacting the life sciences market and how companies are reacting.

Capan discusses the industry is embracing new technologies and how these use cases may evolve in the coming year.